Proactive Investors - Run By Investors For Investors

Amryt Pharma given permission to extend age eligibility for drug trial

Amryt is developing AP101 as a potential treatment for Epidermolysis Bullosa, where skin blisters to the touch
baby
The condition is often present from birth

Amryt Pharma PLC (LON:AMYT) said it has been given permission to extend the age eligibility for its Phase III trial of a drug to treat a rare skin condition.

The study’s independent data monitoring committee has concluded that children aged between 21 days and four years can take part in the programme.

READ: Amryt Pharma adds new element to promising portfolio

Amryt is developing AP101 as a potential treatment for Epidermolysis Bullosa, where skin blisters to the touch.

The company’s chief executive, Joe Wiley, called the committee’s decision “a significant step forward”, adding it could help address an unmet need for a devastating condition, often present from birth.

“This development represents another milestone for Amryt as we build on our vision of becoming a global leader in rare and orphan diseases," he went on.

In a note to clients, analysts at ‘house’ broker Shore Capital said the update “demonstrates continued momentum at Amryt, following the significant positive interim efficacy update” at the start of January.

They added; “We continue to view Amryt as a compelling investment opportunity to gain exposure to a diversified rare disease platform, with a marketed drug for an ultra-rare disease, a further de-risked Phase III asset in an untapped $1bn market opportunity, and an attractive pre-clinical gene therapy platform.

“Our risk-adjusted sum-of-the-parts valuation suggests Lojuxta alone is worth c.20p/share, with the Phase III EB asset and early-stage pipeline not reflected.”

In early afternoon trading, Amryt Pharma shares were 0.3% higher at 15.55p.

 -- Adds analyst comment, share price --

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
patch
May 19 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use